ASPE ISSUE BRIEF Health Care Cost Containment and Medical Innovation May 2012 By: Amber Jessup, Ph.D.
Drug Development
Reports
Displaying 11 - 20 of 29. 10 per page. Page 2.
Advanced SearchExpanding the Use of Generic Drugs
ASPE ISSUE BRIEF Expanding the Use of Generic Drugs By: ASPE Staff December 1, 2010
Medicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries
U.S. Department of Health and Human Services
Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
U.S. Department of Health and Human Services
Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings Immune globulin intravenous (IGIV), also referred to as intravenous immune globulin (IVIG), is a valuable treatment for many seriously ill patients. Although the U.S.
Cost Effectiveness Considerations in the Approval and Adoption of New Health Technologies
Contents Background and Purpose Methodology Summary of Key Findings and Stakeholder Suggestions Conclusions and Policy Implications A.
Continuation of Drug Risk Adjustment
Prepared by: National Opinion Research Center (NORC) at the University of Chicago Prepared for:U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
Compendium of Home Modification and Assistive Technology Policy and Practice Across States: Final Report
U.S. Department of Health and Human Services
Evaluation of New Measures of Assistive Technology and the Home Environment from the 2005 Pilot Study of Technology and Aging
U.S. Department of Health and Human Services